CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 219 enrolled
Drug / intervention
PF-06700841 +1 moredrug
Likely dose
PF-06700841 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03963401
NCT03963401Phase 2Completed
CompareCT.gov

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

Pfizer·interventional·Posted May 24, 2019·Updated Aug 4, 2021

In Brief

A Phase 2 clinical trial evaluating PF-06700841 and Placebo for Psoriatic Arthritis. Completed, enrolled 219 participants across 48 sites in 11 countries.

Detailed Summary

This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesAustralia, Bulgaria, Czechia, Estonia, Hungary, Lithuania, Poland, Russia, Serbia, Slovakia, Spain
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 24, 2019
Enrollment StartJun 13, 2019
Primary CompletionApr 6, 2020
Study CompletionJan 15, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.1 years ago

Interventions

PF-06700841drug

Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

Placeboother

Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.